Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, and Katerina Politi

Abstract

Purpose: The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and afatinib, have transformed the treatment of advanced EGFR-mutant lung adenocarcinoma. However, almost all patients who respond develop acquired resistance on average approximately 1 year after starting therapy. Resistance is commonly due to a secondary mutation in EGFR (EGFRT790M). We previously found that the combination of the EGFR TKI afatinib and the EGFR antibody cetuximab could overcome EGFRT790M-mediated resistance in preclinical models. This combination has shown a 29% response rate in a clinical trial in patients with acquired resistance to first-generation TKIs. An outstanding question is whether this regimen is beneficial when used as first-line therapy.

Experimental Design: Using mouse models of EGFR-mutant lung cancer, we tested whether the combination of afatinib plus cetuximab delivered upfront to mice with TKI-naïve EGFRex19del-driven lung adenocarcinomas delayed tumor relapse and drug-resistance compared with single-agent TKIs.

Results: Afatinib plus cetuximab markedly delayed the time to relapse and incidence of drug-resistant tumors, which occurred in only 63.6% of the mice, in contrast to erlotinib or afatinib treatment where 100% of mice developed resistance. Mechanisms of tumor escape observed in afatinib plus cetuximab resistant tumors include the EGFRT790M mutation and Kras mutations. Experiments in cell lines and xenografts confirmed that the afatinib plus cetuximab combination does not suppress the emergence of EGFRT790M.

Conclusions: These results highlight the potential of afatinib plus cetuximab as an effective treatment strategy for patients with TKI-naïve EGFR-mutant lung cancer and indicate that clinical trial development in this area is warranted. 

Introduction

Tyrosine kinase inhibitors (TKIs), such as erlotinib and afatinib, are approved for first-line treatment of lung adenocarcinomas induced by mutations in exons encoding the tyrosine kinase domain of EGFR. The most common lung adenocarcinoma-associated EGFR mutations are either in-frame deletions in exon 19 that eliminate an LREA motif in the protein (EGFRex19del) or a point mutation in exon 21 that results in the substitution of a leucine for an arginine at position 858 (EGFRL858R). These mutations cause conformational changes in the EGFR kinase domain leading to activation of the receptor tyrosine kinase. Erlotinib is a reversible EGFR-TKI that blocks activation of the receptor by competing with adenosine triphosphate (ATP) for binding to the ATP-binding pocket of the receptor. Afatinib, another ATP inhibitor, binds EGFR covalently, to irreversibly block the activity of EGFR. The clinical success of these reversible and irreversible TKIs for the treatment of EGFR-mutant lung adenocarcinomas lies in their higher binding affinity for mutant EGFR (EGFRex19del and EGFRL858R) than wild-type EGFR (1, 2).

While most patients with EGFR-mutant lung adenocarcinoma experience significant clinical benefit and radiographic response to treatment with EGFR TKIs, median progression-free survival is approximately 12 months (3, 4). In the majority of drug-resistant tumors, the mutant EGFR allele has acquired a secondary point mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain (5). The EGFRT790M mutation restores the receptor affinity for ATP to wild-type levels, thus reducing the effect of the TKI (6).
New-generation mutant-specific TKIs, such as AZD9291 and CO-1686, are showing clinical activity especially in the setting of T790M-positive disease (7–10).

A previous study conducted in transgenic mice with EGFR<sup>L858R–T790M</sup>–induced lung adenocarcinomas demonstrated that a combination of a second-generation TKI afatinib and the anti-EGFR antibody cetuximab can overcome T790M-mediated resistance, while neither drug alone is effective (11). On the basis of these data, a phase IB/II clinical trial of this drug combination was conducted in patients that developed progressive disease after erlotinib or gefitinib (12). The given promising results in the resistance setting as well as data in the first-line setting presented in this article, a randomized phase II/III trial of afatinib plus cetuximab versus afatinib alone in treatment-naïve patients with advanced EGFR-mutant lung cancer is ongoing led by the South West Oncology Group (SWOG).

We hypothesize that patients may derive an even greater benefit from upfront treatment with the combination of afatinib plus cetuximab, with the goal of delaying the development of resistance. Here, we investigated the therapeutic effect of first-line afatinib plus cetuximab combination therapy versus erlotinib or afatinib alone in a mouse model of lung cancer driven by EGFR<sup>L858R</sup>, which we previously developed (13).

**Transgenic Relevance**

The first-generation tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib have improved progression-free survival in patients with lung adenocarcinomas harboring activating mutations in the EGFR gene. Despite the effectiveness of these compounds, patients inevitably develop progressive disease after a median of approximately 1 year of starting treatment. Effective strategies to delay the emergence of this resistance are needed. Here, we report on a preclinical study that demonstrates how the combination of the EGFR TKI afatinib and the EGFR antibody cetuximab decreases the incidence and delays drug resistance in transgenic mouse models of EGFR-mutant lung cancer. This work lays the foundation for a clinical trial of the combination of afatinib and cetuximab in patients with TKI-naïve EGFR-mutant lung cancer.

**Materials and Methods**

**Transgenic mice**

TetO-EGFR<sup>L858R</sup> mice and CCSP-<i>rT</i>A mice were previously described (13). Doxycycline was administered by feeding mice with doxycycline-impregnated food pellets (625 ppm; Harlan Tekland). Erlotinib and afatinib (obtained from the Organic Synthesis Core Facility at MSKCC, NY) were suspended in 0.5% w/v methylcellulose. Erlotinib was administered intraperitoneally (i.p., 25 mg/kg, 5 days a week) while afatinib was administered orally (per os, 25 mg/kg, 5 days a week). Cetuximab (Erbitux; Bristol-Myers Squibb and Eli Lilly Pharmaceuticals) was administered intraperitoneally (i.p., 1 mg twice a week). Our initial intent was to compare afatinib plus cetuximab to erlotinib, therefore mice were randomized to treatment with these agents. Afatinib treatment was included later as we began to develop the concept of the first-line trial of afatinib versus afatinib plus cetuximab. At the end of the study, mice were euthanized by CO2 asphyxiation. All animals were kept in pathogen-free housing under guidelines approved by the Yale University Institutional Animal Care and Use Committee (IACUC).

**Magnetic resonance imaging**

All procedures were performed in accordance with protocols approved by the Yale University IACUC and in agreement with the NIH Guide for the Care and Use of Laboratory Animals. Respiratory gated, gradient-echo MR images of mice were collected with a 4T (31-cm bore) small-animal Bruker horizontal-bore spectrometer (Bruker AVANCE). All data were collected using T<sub>1</sub>-weighted contrast using a custom-built 4 cm diameter 1H Bollinger coil. Prior to the imaging experiments, mice were anesthetized with isoflurane and were maintained on isoflurane/O<sub>2</sub> (2–2.5% v/v) throughout data collection. Animal core-body temperature was maintained at 37 ± 1°C by circulation of warm air through the bore of the magnet. Although during the MR imaging, the respiration rates for all mice were regular, MR data collection was synchronized with animal respiration using an MR compatible small-animal monitoring and gating system (SA Instruments, Inc), which allowed MRI acquisition in the same phase of the breathing cycle. All the MR images were collected during postexpiratory periods with the following MR parameters: field of view = 2.56 × 2.56 × 1.80 cm<sup>3</sup>, image matrix = 256 × 128 × 24, repetition time = 100 ms, echo time = 4.5 ms, flip angle = 30 degrees, 2 averages. These scan parameters were chosen to maximize the contrast between healthy lung tissue and tumor. Following a treatment period, mice in different treatment groups were scanned repeatedly over weeks off drug to evaluate the presence of recurrent tumors. Tumor volume was quantified by calculating the area of visible lung opacities present in each image sequence per mouse using BioImage Suite 3.01 (14).

**Sequencing**

Freshly harvested tumors and adjacent normal lung tissue were pulverized in liquid nitrogen and RNA was extracted using the RNeasy platform (Qiagen, #74104). DNA was then treated with DNase I (RNase-Free DNA Set, Qiagen #79294). cDNA was synthesized using the Superscript III First-Strand cDNA Synthesis Kit (Invitrogen, #18080-051). The cDNA was used as template to amplify the EGFR transgene and Kras cDNA. PCR products were sequenced by Sanger sequencing and sequence tracings were manually reviewed in the forward and reverse directions. The presence of the EGFR<sup>L858R</sup> mutation was confirmed with the following primers: EGFR-2445F: 5'-caactggtgtgtgcagatcg-3', EGFR-3616R: 5'-cagtctggagggaggagc-3'. The presence of the EGFR<sup>T790M</sup> mutation was evaluated using the following primers: EGFR-2074F: 5'-ttacctacccaggaggagc-3', EGFR-2502R: 5'-cacaaggaaggtctccca-3'. The presence of Kras mutations were evaluated using the following primers: Kras-Fw: 5'-aagaaggctgctgaaatg-3', Kras-432Rv: 5'-ccctccccagttctcatgta-3'. Mutations in genes encoding the mouse Pi3k catalytic subunit alpha (Pik3ca) and beta (Pik3cb) were investigated using the following oligos: Pik3ca-F1: 5'-ggcctggggaaacataaact-3', Pik3ca-R1: 5'-ccctccagctgctgcgct-3', Pik3ca-F3: 5'-ttctgaccaaacagacactag-3', Pik3cb-F2: 5'-ttagcttaagaaatcctg-3', Pik3cb-R2: 5'-ggggccagaggttaagatc-3'.
Cell lines and in vitro EGFR<sup>T790M</sup> selection

Human lung adenocarcinoma cell lines, PC-9 and PC-9/BRc1 were cultured in RPMI + l-glutamine (Corning), supplemented with 10% heat-inactivated FBS (Atlanta Biologicals) and 1% penicillin/streptomycin (Corning). PC-9 cells were obtained from the Varmus Laboratory and maintained in the Pao laboratory since 2004. The isogenic afatinib-resistant cell line PC-9/BRc1 was derived from parental PC-9 cells as previously described (15). Both cell lines were routinely tested for mycoplasma contamination and authentication was performed by confirming the presence of the predicted EGFR kinase domain mutations and using STR profiling (GenePrint 10 System) at the Yale University DNA Analysis Facility in July 2015.

Aliquots of cell mixtures containing 75% PC-9 parental cells (T790M-negative) and 25% PC-9/BRc1 cells (T790M-positive) were prepared and plated in separate dishes. One aliquot was saved as the pretreatment sample to empirically determine the starting T790M allele frequency. Cell mixtures were harvested following 7 days of treatment with EGFR inhibitors. Drugs were refreshed every 72 hours. Genomic DNA was extracted using the DNeasy kit (Qiagen #69504) and was subjected to SNAPshot sequencing for T790M (16). T790M allele frequency was determined by measuring the relative heights of T790M mutant versus wild-type EGRF peaks [(mutant peak height) / (mutant + wild-type peak height)].

 Xenografts and in vivo EGFR<sup>T790M</sup> selection

Aliquots of cell mixtures containing 75% PC-9 parental cells (T790M-negative) and 25% PC-9/BRc1 cells (T790M-positive) were prepared. Eight-week-old athymic nude mice were injected subcutaneously with 10 million cells from the mixture. When tumors reached approximately 250 mm<sup>3</sup>, animals were randomized for immediate tumor harvesting or to receive either vehicle or the combination of afatinib (p.o., 25 mg/kg, once a week) and cetuximab (i.p., 50 mg/kg, twice a week) for 10 days. Tumor samples were collected after 10 days of treatment and flash-frozen in liquid nitrogen. Genomic DNA was extracted by phenol–chloroform extraction and subjected to SNaPshot sequencing for T790M (16). T790M allele frequency was determined by measuring the relative heights of mutant versus wild-type EGRF peaks at the 2369 EGRF residue [(mutant peak height)/(mutant + wild-type peak height)].

Real-time PCR

Real-time PCR was used to determine the levels of expression of the Egrf transgene in the tumors and normal adjacent lungs using the Viia7 Real Time PCR System (Applied Biosystems) and the prespecified TaqMan assay Hs01076078_m1. RNA was extracted using the RNeasy kit according to the manufacturer’s protocol (Qiagen, #74104). cDNA was synthesized from DNase I-treated RNA using the SuperScript III First-Strand cDNA Synthesis Kit (Invitrogen). Fifteen nanograms of cDNA were used in the reaction (amplification 40 cycles, 2 minutes at 50°C, 10 minutes at 95°C, 15 seconds at 95°C, 1 minute at 60°C). Quadruplicate C<sub>T</sub> values were averaged and normalized to mouse β-actin (TaqMan, Acb 4352933E).

Histology and immunohistochemistry

After sacrifice, normal and tumor lung were macrodissected and fixed in 4% paraformaldehyde overnight at room temperature, placed in 70% ethanol, and sent for paraffin embedding and sectioning (Histology @ Yale). Four micrometer sections were used for hematoxylin and eosin (H&E) and phospho-histone H3 (1:200, CST #9701) staining.

Immunoblotting

Crushed tumors were lysed in ice-cold RIPA lysis buffer [50 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 5 mmol/L MgCl<sub>2</sub>, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, protease and phosphatase inhibitor cocktail (Thermo Scientific)]. Equal amounts of total protein were separated by SDS-PAGE and probed as indicated. Signals were detected using either SuperSignal West Pico or Femto chemiluminescent substrates (Pierce Biotechnology). Antibodies for immunoblotting against EGFR<sup>EGFR-L858R</sup> (#3197), phospho-EGFR-Y1068 (#2234), phospho-Erbb2-Y1248 (#2247), AKT (#2983), phospho-AKT (#4060), ERK1/2 (#9102), phospho-ERK (#4376), S6 (#2217), phospho-S6 (#364), G6PDH (#2118), and the secondary anti-rabbit HRP antibody (#7074) were from Cell Signaling Technology. Additional antibodies were ErbB2 (Millipore, 06-562) and SPC (Abcam, #ab90716). All the antibodies were used at the dilutions suggested by the manufacturer.

Statistical analysis

Statistical analysis was performed with GraphPad Prism 6.0 software with the appropriate tests as indicated in the text and figure legends.

Results

Aftatinib plus cetuximab combination therapy delays relapse compared with erlotinib or afatinib alone

As a first step in testing whether the afatinib plus cetuximab combination was more effective than single-agent TKIs in the initial treatment of EGFR-mutant lung cancer, we measured tumor relapse following treatment with the different regimens. CCSP-<sup>TetO-EGFRL858R</sup> tumor-bearing mice were treated with afatinib plus cetuximab, afatinib, or erlotinib for 4 weeks, after which treatment was interrupted (Fig. 1). Doxorubicin treatment, to induce transgene expression was initiated at weaning and maintained throughout the life of the mice. To evaluate response to each treatment, tumor volume was quantified by MRI at the beginning and at the end of the 4 weeks of treatment. MR images taken at the end of the treatment period showed dramatic responses in all three treatment groups: the median tumor volume change in the treatment groups: the median tumor volume change on erlotinib,
afatinib, and afatinib plus cetuximab was 100% (Supplementary Fig. S1A and S1B; Supplementary Table S1).

After 4 weeks, treatment was halted and mice were monitored by MRI 4, 8, and 12 weeks off drug to evaluate the presence of recurrent tumors (Fig. 1). In some cases, imaging was performed before the 4-week interval was complete as the mice were showing signs of respiratory distress. After 4 weeks off drug, only 15.4% of the afatinib plus cetuximab-treated mice showed measurable recurrent tumors (defined as tumor volume > 100 mm³), in contrast to 77.8% of afatinib-treated and 100% of erlotinib-treated mice. This percentage increased to 84.6% after 8 weeks off drug in the afatinib plus cetuximab group and reached 100% after 12 weeks off-drug (Fig. 1). By 8 weeks off drug, tumors in all mice treated with afatinib as a single agent had recurred. The median tumor burden pretreatment in the afatinib plus cetuximab group was similar to that in the erlotinib and afatinib (erlotinib 225.7 mm³, afatinib 320.7 mm³, afatinib plus cetuximab 206.7 mm³) groups, indicating that the longer time to relapse was not a function of the initial tumor volume (Supplementary Fig. S1; Supplementary Table S1). These data show that afatinib plus cetuximab delays tumor re-emergence by 2-fold in our mouse model of EGFR-mutant lung cancer when compared with erlotinib and afatinib, indicating that the drug combination is more potent than the single agents in eradicating tumor cells.

Generation of afatinib plus cetuximab-resistant lung adenocarcinomas

To investigate whether long-term afatinib plus cetuximab treatment of EGFR<sup>L858R</sup>-mutant lung adenocarcinomas in mice leads to the emergence of drug-resistant tumors, we subjected mice with EGFR<sup>L858R</sup>-induced lung adenocarcinomas to an intermittent drug-dosing schedule, previously used to successfully generate erlotinib-resistant tumors (17). Mice were treated with erlotinib, afatinib, or afatinib plus cetuximab for 4 weeks after drug withdrawal, and then drug treatment was reinitiated for another 4 weeks. This on/off drug treatment cycle was repeated until the emergence of resistance or for a maximum of 5 times (Fig. 2A; Supplementary Tables S2 and S3). All seven mice intermittently treated with erlotinib developed resistance within 4 drug cycles, confirming previously published results (ref. 17; Fig. 2B). The emergence of drug resistance was also observed in all 5 mice treated with afatinib (Fig. 2B). Consistent with these data, our results indicate that afatinib induces resistance and does not delay the onset of resistance compared with erlotinib (Fig. 2B and C). The emergence of resistance to afatinib plus cetuximab was evaluated in 13 CCSP-rtTA; TetO-EGFR<sup>L858R</sup> mice. The afatinib plus cetuximab drug combination was well tolerated by mice treated with the intermittent dosing protocol as evidenced by their weight patterns compared with TKI treatment alone (Supplementary Fig. S2). Six out of 13 mice that went through at least 3 cycles of afatinib plus cetuximab did not develop resistant disease (Fig. 2B; Supplementary Table S3). Four out of 11 mice that went through at least 4 cycles of afatinib plus cetuximab, did not develop resistant disease (Fig. 2B; Supplementary Table S3). Therefore, in contrast to erlotinib and afatinib, resistance to afatinib plus cetuximab occurred only in 63.6% (7/11) of mice that went through the same minimum number of drug cycles. As afatinib plus cetuximab delayed tumor relapse, each off-drug cycle...
was extended in this cohort of mice. Therefore, in the afatinib plus cetuximab-treated mice, the overall time for resistant tumors to emerge was longer (>2-fold) compared with those treated with single agent (Fig. 2C). In summary, our data reveal that drug resistance is delayed and occurs with decreased incidence in mice treated with afatinib plus cetuximab compared with single-agent TKIs.

*EGFR<sup>T790M</sup>* and *Kras* mutations are found in afatinib plus cetuximab-resistant lung adenocarcinomas

To investigate the mechanisms of resistance in tumors that grew out following an initial response to EGFR inhibitor treatment, drug-resistant tumors generated using either continuous (data not shown) or intermittent dosing of the drugs were collected for molecular analysis and histopathologic evaluation. In some cases, multiple resistant tumors per mouse were observed by MRI and at the time of necropsy. However, in most cases only one nodule was large enough for molecular studies. We first evaluated whether EGFR<sup>T790M</sup> could account for drug resistance in all three groups of treatment. For this purpose, we extracted RNA from the resistant tumors and the adjacent normal lung and generated cDNA that was used to sequence the TK domain of EGFR. All the erlotinib (*n* = 4) and the afatinib (*n* = 6) resistant tumors analyzed contained the cytosine to thymine

---

**Figure 2.** Generation of erlotinib, afatinib, or afatinib plus cetuximab-resistant tumors. A, schematic representation of the intermittent dosing protocol used to generate acquired resistance to erlotinib, afatinib, and afatinib plus cetuximab in CCSP-rtTA; TetO-EGFR<sup>T790M</sup> mice. Doxycycline administration was initiated at weaning and subsequently kept constant throughout the life of the animal. Tumor response was evaluated by MRI at the beginning and at the end of every drug treatment cycle (see Materials and Methods for details). Intermittent drug dosing was repeated until the emergence of resistance. Coronal MR images of a mouse subjected to intermittent afatinib plus cetuximab treatment are shown. Tumor volume measurements are at the bottom of each image (H, heart; nod, nodule). B, line chart showing the treatment schedule of individual mice. Mice were treated 5 days a week for 4 weeks, as highlighted by horizontal lines (in blue, erlotinib treatment; in red, afatinib treatment; in green, afatinib plus cetuximab treatment), and then stopped. Treatment was resumed at disease recurrence as assessed by MRI and clinical presentation. R, mice that developed resistance to treatment; N, mice that were sacrificed because they did not develop resistance after 4 to 5 cycles of treatment or were still showing a complete response after the third cycle. C, scatter plot showing the time to disease recurrence as assessed by MRI and clinical presentation. R, mice that developed resistance to treatment; N, mice that were sacrificed because they did not develop resistance after 4 to 5 cycles of treatment or were still showing a complete response after the third cycle.
point mutation at position 2369, leading to the T790M amino acid substitution. Interestingly, the same mutation was detected in only 7 out of 13 afatinib plus cetuximab-resistant tumors studied (53.8%; Table 1; Supplementary Fig. S3A). All matched adjacent normal lungs from the same animals were negative for EGFRT790M (Table 1; Supplementary Fig. S3A). Expression of the EGFR\textsuperscript{T790M} mutant was confirmed in all the resistant tumors and adjacent lungs as expected (Supplementary Fig. S3B).

These data suggest that afatinib plus cetuximab treatment does not suppress the emergence of EGFRT790M even though it delays its emergence. To further explore this possibility, we performed mixing experiments in cell culture, in which PC-9 cells (T790M negative) and TKI-resistant PC-9/BRC1 cells (T790M positive) were mixed in a 3:1 ratio. The cells were then treated with afatinib, cetuximab, or afatinib plus cetuximab for 1 week, after which the T790M allele frequency was determined. Consistent with data from the transgenic mice, we found that afatinib and afatinib plus cetuximab treatment both selected for EGFRT790M to a similar extent (Fig. 3A).

We further examined EGFRT790M selection in a xenograft model by injecting a 3:1 ratio of PC-9 cells and PC-9/BRC1 cells into the flanks of immunodeficient mice and treating animals with afatinib plus cetuximab for 10 days. By comparing T790M allele frequency pre- and post-treatment, we again found that afatinib plus cetuximab selected for T790M in vivo (Fig. 3B). Interestingly, in these mixing experiments, the abundance of T790M in the afatinib plus cetuximab treatments did not differ from the single-agent studies, in contrast to results in the transgenic mice. This can potentially be explained by this experimental design in which cells with the T790M mutation are mixed with cells without it facilitating the emergence of T790M compared with transgenic mice where the mutation must arise spontaneously. In summary, our data are consistent with the notion that an increase in T790M allele frequency may mediate resistance to treatment with afatinib plus cetuximab in a subset of cases.

We further explored mechanisms of resistance to afatinib plus cetuximab in the remainder of T790M-negative drug-resistant tumors. As resistance to cetuximab treatment has been reported to occur via KRAS mutations in metastatic colorectal cancer (18), we checked whether mutations in this gene could be associated with resistance to afatinib plus cetuximab, especially in those tumors without EGFRT790M mutations. For this purpose, we sequenced endogenous Kras in all the resistant tumors and normal adjacent lung. Interestingly, 5 resistant tumors that were negative for the T790M mutation had acquired a point mutation that changed the glycine amino acid at position 12. We detected a guanine-to-thymine transversion at position 35, leading to G12V, and three guanine-to-adenosine transition at position 35, leading to G12D, and three guanine-to-adenosine transition at position 35, leading to G12D (Table 1; Supplementary Fig. S3C). Importantly, these tumors with Kras mutations retained production of the EGFR L858R protein (Fig. 3C).

As MET, ERBB2, or EGF amplification are also associated with resistance to EGFR TKIs (19–21), we looked at alterations in copy number of these genes in the resistant tumors and normal adjacent lung. None of resistant tumors showed amplification of Met, Erbb2, or Egr (Supplementary Fig. S3D). However, variations in the levels of expression of Egr were found in one afatinib-resistant tumor that displayed a 3-fold increased expression level, and two afatinib plus cetuximab-resistant, and that had approximately 3-fold increased level of expression of the human transgene (Supplementary Fig. S3E). Increased EGR copy number has also been described in human EGFR-mutant TKI-resistant lung adenocarcinomas (21, 22).

**Signaling pathway activation in resistant tumors**

Blockade of EGFR by targeted therapy results in the inhibition of the MAPK/ERK as well as the PIK3/akt pathways in tumor cells. By gaining the somatic T790M mutation, such cells maintain activation of these downstream pathways. To confirm this scenario in our samples, we performed immunoblotting on lysates from untreated, drug-sensitive and resistant tumors (Fig. 3C). Indeed, phosphorylated EGFR levels were restored to untreated levels in EGFR\textsuperscript{T790M} positive tumors but not in those harboring a Kras mutation. Interestingly, the EGFR\textsuperscript{T790M} tumors also showed increased ErbB2 phosphorylation that was not detected in the Kras-mutant tumors. In the Kras-mutant tumors, instead, elevated phospho-Erk levels were found (Fig. 3C). Staining for the mitotic marker phospho-histone H3 on tumor

<table>
<thead>
<tr>
<th>Mouse</th>
<th>Drug treatment</th>
<th>Sample</th>
<th>Primary EGFR mutation</th>
<th>Secondary EGFR mutation</th>
<th>Kras mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>6501</td>
<td>E</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>8814*</td>
<td>E</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>8817*</td>
<td>E</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>8818*</td>
<td>E</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>9194</td>
<td>A</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>9196</td>
<td>A</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>1100</td>
<td>A</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>4392</td>
<td>A+C</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>G12R</td>
</tr>
<tr>
<td></td>
<td>Nodule 2</td>
<td>L858R</td>
<td>T790M</td>
<td>G12R</td>
<td>G12D</td>
</tr>
<tr>
<td>4973</td>
<td>A+C</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
</tr>
<tr>
<td></td>
<td>Nodule 2</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
<td>G12D</td>
</tr>
<tr>
<td>597</td>
<td>A+C</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
</tr>
<tr>
<td></td>
<td>Nodule 4</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
<td>G12D</td>
</tr>
<tr>
<td>5953</td>
<td>A+C</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
<td>G12D</td>
</tr>
<tr>
<td>7087</td>
<td>A+C</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
</tr>
<tr>
<td></td>
<td>Nodule 1</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
<td>G12D</td>
</tr>
<tr>
<td>7091</td>
<td>A+C</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
</tr>
<tr>
<td></td>
<td>Nodule 2</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
<td>G12D</td>
</tr>
<tr>
<td>9072*</td>
<td>A+C</td>
<td>Normal</td>
<td>L858R</td>
<td>T790M</td>
<td>G12D</td>
</tr>
</tbody>
</table>

Abbreviations: E, erlotinib; A, afatinib; A+C, afatinib+cetuximab.

*Mice underwent continuous and not intermittent drug treatment.

Table 1. Summary of resistance mechanisms in murine drug-resistant tumors

*Published OnlineFirst September 4, 2015; DOI: 10.1158/1078-0432.CCR-15-0620"
sections revealed active proliferation in EGFRT790M positive and Kras
-mutant afatinib plus cetuximab-resistant tumors, indicating that regardless of the mechanism these tumors have escaped drug treatment allowing them to proliferate (Fig. 3D).

Lung adenocarcinomas with somatic mutations in EGR are characterized by activation of the P13K–AKT–mTOR pathway (23) that can be further engaged in settings of resistance to TKIs and thus attenuate apoptosis and enhance proliferation (24). To investigate the contribution of the mTOR pathway to resistance to afatinib plus cetuximab, we performed immunoblotting for pS6, a widely used marker of mTOR activation. After 5 days of treatment with erlotinib or afatinib alone and afatinib plus cetuximab decreased levels of pS6 were observed. We did not observe an increase in the pS6 levels in resistant tumors, consistent with the mutationally driven mechanisms of resistance found (Fig. 3C).

Discussion

The emergence of acquired resistance to single-agent EGFR TKI inhibitor treatment is the barrier to achieving long-term benefit from these targeted therapies in patients with EGFR-mutant lung cancer. Therefore, there is an urgent need for therapeutic regimens that can delay or prevent the emergence of drug resistance. Here
we show that dual targeting of mutant EGFR with the irreversible TKI afatinib and the EGFR antibody cetuximab in the first-line setting reduces the incidence and delays drug resistance in mice with EGFR<sup>L858R</sup>-induced lung adenocarcinomas. Moreover, we investigated mechanisms of resistance in these afatinib plus cetuximab-resistant tumors. Our data highlight the potential of this drug combination for the first-line treatment of patients with EGFR-mutant lung cancer.

Several new strategies and drugs have been developed in recent years aimed at overcoming resistance to first and second-generation TKIs. The afatinib plus cetuximab combination was originally found to lead to tumor regression in transgenic mice harboring EGFR<sup>L858R–T790M</sup>-induced lung adenocarcinomas (11). In a clinical trial of this combination, 29% of patients with TKI-refractory lung adenocarcinomas (both with and without the T790M mutation) responded to these agents (12). One of the disadvantages of this combination, however, is the increased toxicity observed due to inhibition of wild-type EGFR. More recently, third-generation EGFR TKIs, such as AZD9291 and CO1686, which specifically target mutant EGFR, including the EGFR<sup>T790M</sup> mutation, have been developed and are showing promise in clinical trials in patients with TKI-resistant EGFR-mutant tumors (7–10). While it is at present unknown how to best sequence these different therapies, emerging preclinical studies suggest that appropriate sequencing of the agents will be important (25). Indeed, resistance to erlotinib, afatinib, and afatinib plus cetuximab can be overcome using the third-generation TKI AZD9291, but the reverse does not occur (25). Together with this information, our data indicate that afatinib plus cetuximab is superior to afatinib or cetuximab alone when used as first-line therapy, suggesting a potential treatment scenario in which afatinib plus cetuximab are given upfront followed by third-generation TKI treatment if and when resistance emerges. A Cooperative group phase II/III trial of afatinib plus cetuximab versus afatinib alone in patients with TKI-naive EGFR-mutant lung cancer is underway. Patients with Exon 19 deletion mutant tumors exhibit improved survival upon upfront afatinib treatment (26) and whether they benefit differently from combined afatinib plus cetuximab treatment compared with patients with L858R-induced tumors remains to be determined. Of note, our study compares afatinib versus afatinib plus cetuximab in mice harboring the L858R point mutation and not EGFR Exon 19 deletion mutations.

Afatinib plus cetuximab can effectively lead to the regression of tumors harboring the EGFR<sup>T790M</sup> mutation (11). Prior to this work, however, it was unclear whether this mutation could emerge as a mechanism of resistance to afatinib plus cetuximab upon treatment of TKI-naïve tumors. We show that in mice with EGFR<sup>L858R</sup>-induced tumors, long-term treatment with afatinib plus cetuximab can lead to the emergence of EGFR<sup>T790M</sup>. Further supporting this result, when we mixed cells with and without EGFR<sup>T790M</sup> and treated them with afatinib plus cetuximab, cells harboring EGFR<sup>T790M</sup> outgrew the EGFR<sup>T790M</sup>-negative cells. Our data support the possibility that one of the mechanisms of resistance to this drug combination is the EGFR<sup>T790M</sup> mutation, a finding that will be confirmed in the clinical trial of this drug combination. These results, also suggest that additional mediators of sensitivity and resistance to afatinib plus cetuximab are likely to exist since we know that tumors harboring EGFR<sup>T790M</sup> mutations can be responsive to this drug combination in mice and humans (11, 12).

Previously, we had found mTOR pathway activation as a mechanism of resistance to afatinib plus cetuximab in tumors already harboring an EGFR<sup>T790M</sup> mutation (24). Interestingly, in the afatinib plus cetuximab-resistant tumors examined here, we did not observe activation of this pathway above baseline levels (Fig. 3C). This is likely due to the fact that all of the resistant tumors examined in this study either had acquired the EGFR<sup>T790M</sup> mutation or a Kras mutation and suggests that the mechanisms of resistance to afatinib plus cetuximab in TKI-naïve and resistant tumors may be different. Importantly, our study points to specific potential resistance mechanisms that should and will be examined in the phase II/III cooperative group trial of afatinib versus afatinib plus cetuximab.

One of the surprising findings from our study was that approximately 50% of afatinib plus cetuximab-resistant tumors in the EGFR<sup>L858R</sup> mouse model harbored mutations in Kras. Mutations in Kras are a well-established mechanism of primary resistance to EGFR TKIs (27), but have not been found to emerge following successful TKI treatment (e.g., acquired resistance) in patients (28). Previously, we found that Kras mutations could emerge in transgenic models of EGFR-mutant lung cancer following erlotinib treatment (17). The discrepancy between humans and mice could be due to the fact that Kras mutations can arise spontaneously in aged mouse lungs (29); thus, it is possible that the Kras-mutant tumors arise independently of EGFR mutations and/or drug treatment. Alternatively, we cannot exclude that the afatinib plus cetuximab drug regimen may contribute to the emergence of Kras mutations. Indeed, Kras mutations have been identified in colorectal cancers that have acquired resistance to cetuximab (18). EGFR and Kras mutations are mutually exclusive in human lung cancer, possibly reflecting the lethality of expressing mutations in both genes (30). In the resistant tumors, however, suppression of EGFR activity may be permissive for the survival of Kras-mutant cells. Analysis of samples from the clinical trials of these agents will further shed light on this issue. Although the EGFR<sup>T790M</sup> mutation and Kras mutations were the only mechanisms of resistance identified in our study, we expect that a broader array of mechanisms will be found in the context of the planned phase II/III clinical trial. Indeed, plans for the molecular analysis of repeat biopsy specimens at the time of acquired resistance to afatinib plus cetuximab in this trial include whole exome sequencing, analysis of receptor tyrosine kinase amplification and protein levels and will provide a comprehensive picture of the mechanistic basis for resistance to these agents in patients with EGFR-mutant lung cancer.

In conclusion, further investigation of the afatinib plus cetuximab combination therapy for patients with untreated EGFR-mutant lung cancer warrants investigation, despite the potential for added toxicity, and may represent an alternative to single-agent TKI treatment that could delay the emergence of drug resistance.

Disclosure of Potential Conflicts of Interest

S.B. Goldberg reports receiving a commercial research grant from AstraZeneca and is a consultant/advisory board member for Clovis. W. Pao is an employee of Roche and reports receiving royalties from MolecularMD. K. Politi reports receiving commercial research grants from AstraZeneca and Kolltan; has ownership interest (including patents) in Molecular MD, and is a consultant/advisory board member for Takeda. No potential conflicts of interest were disclosed by the other authors.


**Grant Support**

This work was funded by NIH/NCI grants R01CA120247 (to K. Politi), R01CA121210 (to W. Pao and K. Politi), P50CA196530-01 (K. Politi and S.B. Goldberg), R01CA140102 (to F. H), P30NS052519 (to F. H), P30CA68485 (to W. Pao), P30CA08748 (to E. de Stanchina), the American Italian Cancer Foundation (to V. Pirazzoli), Uniting Against Lung Cancer (to K. Politi), and Yale University. C.B. Meador was supported by Public Health Service Award T32 GM07347 from the National Institute of General Medical Studies for the Vanderbilt Medical-Scientist Training Program and the VICC Melly Family Scholarship. Sarah Goldberg is funded by the Department of Defense, the Hope Foundation, and AstraZeneca. D. Ayeni was supported by an NSF Predoctoral fellowship (DGE-1122492).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 13, 2015; revised August 14, 2015; accepted August 18, 2015; published OnlineFirst September 4, 2015.

**References**


